1. Home
  2. UPC vs ENTO Comparison

UPC vs ENTO Comparison

Compare UPC & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UPC
  • ENTO
  • Stock Information
  • Founded
  • UPC 1998
  • ENTO 2014
  • Country
  • UPC China
  • ENTO United States
  • Employees
  • UPC N/A
  • ENTO N/A
  • Industry
  • UPC Biotechnology: Pharmaceutical Preparations
  • ENTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • UPC Health Care
  • ENTO Health Care
  • Exchange
  • UPC Nasdaq
  • ENTO Nasdaq
  • Market Cap
  • UPC 2.1M
  • ENTO 1.9M
  • IPO Year
  • UPC 2021
  • ENTO 2016
  • Fundamental
  • Price
  • UPC $3.38
  • ENTO $0.47
  • Analyst Decision
  • UPC
  • ENTO
  • Analyst Count
  • UPC 0
  • ENTO 0
  • Target Price
  • UPC N/A
  • ENTO N/A
  • AVG Volume (30 Days)
  • UPC 33.2K
  • ENTO 1.6M
  • Earning Date
  • UPC 07-25-2025
  • ENTO 05-15-2025
  • Dividend Yield
  • UPC N/A
  • ENTO N/A
  • EPS Growth
  • UPC N/A
  • ENTO N/A
  • EPS
  • UPC N/A
  • ENTO N/A
  • Revenue
  • UPC $19,293,003.00
  • ENTO N/A
  • Revenue This Year
  • UPC N/A
  • ENTO N/A
  • Revenue Next Year
  • UPC N/A
  • ENTO N/A
  • P/E Ratio
  • UPC N/A
  • ENTO N/A
  • Revenue Growth
  • UPC N/A
  • ENTO N/A
  • 52 Week Low
  • UPC $2.51
  • ENTO $0.19
  • 52 Week High
  • UPC $2,423.88
  • ENTO $1.11
  • Technical
  • Relative Strength Index (RSI)
  • UPC 42.03
  • ENTO 51.42
  • Support Level
  • UPC $3.53
  • ENTO $0.44
  • Resistance Level
  • UPC $3.96
  • ENTO $0.51
  • Average True Range (ATR)
  • UPC 0.23
  • ENTO 0.05
  • MACD
  • UPC 0.02
  • ENTO 0.00
  • Stochastic Oscillator
  • UPC 23.08
  • ENTO 53.27

About UPC Universe Pharmaceuticals Inc.

Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: